Parallax Health Sciences Inc. (fka PRLX)

[jonnyvs]

Loading wall from cdel here?

[420man]

It will go..patience

[jonnyvs]

.20 easy as cv fear will increase tonight

[420man]

.20's plus coming here. GL

[jonnyvs]

Here we go. I think there’s a lot left in the tank here. 300k buy at .06 at the open

[Expensivetaste281]

A lot of it , no interest

[jonnyvs]

Needs volume

[gr8investment]

Ground floor here! Could go 5x fast with this float

[georgie18]

PRLX...0062...bidding the 50ma...

[gr8investment]

Coronavirus low float! PRLX!

[420man]

Interesting

[georgie18]

PRLX...055...https://www.otcmarkets.com/stock/PRLX/news ...Parallax Diagnostics Announces Intent to Develop a Rapid Screening Test for COVID-19 on its Patented FDA 510(K) Approved Diagnostic PlatformPress Release |...

[davidsson10]

Parallax Diagnostics Announces Intent to Develop a Rapid Screening Test for COVID-19 on its Patented FDA 510(K) Approved Diagnostic Platform

March 11, 2020 07:00 ET | Source: Parallax Health Sciences, Inc.

Company will Partner to Accelerate The Deployment of Diagnostic Solutions Under Patent Protected Service Areas Including China, Hong Kong, India, and US

NEW YORK, NY, March 11, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Parallax Health Sciences, Inc. (OTCQB: PRLX) (''Parallax'' or the ''Company''), an outcome-driven connected healthcare company, today announced its wholly owned subsidiary Parallax Diagnostics, Inc. will execute a partnership strategy to develop, acquire or license monoclonal and polyclonal antibodies for the creation of a low cost and rapid screening test for COVID-19 (coronavirus disease 2019) to be delivered in conjunction with the manufacturing and distribution of the Company’s patented and proven VT-1000 Immunoassay diagnostic platform.

Dr. David Stark, President of Parallax Diagnostics, stated, “We are seeking partners to accelerate developing a rapid screening test for COVID-19 to meet the urgent demand on a global basis.” Dr. Stark went on to say, “Parallax is uniquely positioned with its FDA 510(K) approved and patented platform to provide low cost and accurate rapid point of care screening tests within patients in mobile and remote environments.”

The COVID-19 outbreak is being closely monitored by the Centers for Disease Control (“CDC)” and the World Health Organization (“WHO”). Parallax Diagnostics is in discussions with both organizations along with private laboratories and universities to assist in facilitating its participation in providing diagnostic solutions for the creation and deployment of mobile rapid screening tests. As an FDA 510(K) approved solution, the Parallax Diagnostics platform goal is to help the medical community to address and combat pandemic viruses and other illnesses through rapid screening tests that are accurate, low in cost and broadband data connected so that remote diagnostics can be performed and reported in real-time and integrated with existing Internet-of-Things, (“IoT”) devices.

Parallax Diagnostics’ goal is in accelerating the development of solutions that aid the medical communities in the United States, China, India, UK, Australia, and other countries.

The following patent families will support this development effort to obtain market share positions in these countries:

FDA Approved and Patented Sparks Handheld Diagnostic Device “Portable Apparatus for Sample Analysis” Patent Numbers CN 101558302, HK 1137813, IN 279743, MO J001298, GB2526749, WO2014144749A1

Patented Good Health Outcomes Remote Patient Monitoring Systems “Data Driven Outcomes” Patent numbers AU2020100161 (A4) GB2526749 (A) US10061812 (B2) US2014280136 (A1) US2018373763 (A1)

About Parallax Diagnostics

Parallax Diagnostics is a bio-medical company and wholly owned subsidiary of Parallax Health Sciences, Inc. Parallax Diagnostics owns a line of 26 FDA approved, Point of Care diagnostic tests on a single platform in the area of infectious disease, cardiac, medical conditions, drugs of abuse, and pregnancy. Parallax Diagnostics is developing a novel, handheld diagnostic testing system that is simple, rapid and elegant, offering the potential to transform the diagnostic landscape by transitioning critical tests from the centralized lab directly to the hands of the physician or clinicians. Our focus is on tests that detect and/or monitor infectious diseases.

About Parallax Health Sciences

Parallax Health Sciences is a leading-edge technology, outcome-driven telehealth company that allows for cost-effective remote diagnosis, treatment, and monitoring of patients through proprietary platforms of integrated products and services. The Company's interoperable novel applications provide patients point-of-care testing and monitoring with information communicated via internet-based mobile phone applications that are agnostic as to operating system and are built on highly sophisticated data analytics. Information is retrieved real-time by physicians who are monitoring patients with chronic diseases or through biometric feedback for health-related behavior modification, and is automated for integration into electronic health records. The Company's products and offerings capitalize on the digital transformation in healthcare for improved patient compliance, diagnosis and treatment, and support healthcare system cost savings and efficiencies. For more information, please visit www.parallaxhealthsciences.com or www.parallaxcare.com.

[willlbone]

Para-slacks getting pulled down.

[Mile High Marauder]

Pretty quiet right now but looking for the news to continue and the stock to heat up!

[TrendTrade2016]

PRLX go long Jedi and watch ya soar

[TrendTrade2016]

PRLX heating up... gonna be a rock star!! After 18c its gonna be sick!!

[TrendTrade2016]

this is why im the greatest trader this site will ever see!!$$$$

[TrendTrade2016]

PRLX boom...love this play!!!!

[TrendTrade2016]

PRLX. Boom

[TrendTrade2016]

PRLX get ready!!

[stocktrademan]

PRLX buy 0.1099

https://parallaxhealthsciences.com/




normal chart









log chart









normal chart








log chart

[TrendTrade2016]

PRLX locked and loaded!!

[conix]

PRLX is raising capital right now. More dilution. But they need the money to continue operating. Raising $6 Million at $0.125 with warrants attached.

[elkonig]

Withrow just banned by the SEC from participating in a public company for 5 years.
Maybe he will pass the scam baton over to his son Kyle now. Like he did over at PTSS.

[lucky, mydog]

oh, but you see, prlx was edvp.

[cantbelieveit]

I'm confused...this does not appear to be about PRLX...was this meant for another board perhaps?

[lucky, mydog]

SEC Charges Medical Diagnostics Company Chairman and Two Others Behind Scheme to Manipulate Company Stock

FOR IMMEDIATE RELEASE
2015-192

SEC complaint
http://www.sec.gov/litigation/complaints/2015/comp-pr2015-192.pdf

Washington D.C., Sept. 14, 2015 — The Securities and Exchange Commission today charged the executive chairman of a Massachusetts-based medical diagnostics company and two others with conducting a pump-and-dump scheme that was ultimately thwarted when the SEC suspended trading in the company’s securities before the secretly controlled shares could be dumped on unsuspecting investors.

The SEC alleges that Edward Withrow III became chairman of the new board of directors at Endeavor Power Corp. in late 2012 after a penny stock company he controlled merged with another controlled by Marco Babini, a Canadian citizen. Withrow and Babini schemed with Samuel Brown, a stock promoter in Idaho, to use Endeavor Power as a vehicle for shaping and carrying out their pump-and-dump scheme.

“We allege that Withrow exploited his executive position to facilitate an elaborate pump-and-dump scheme with Babini and Brown,” said Paul G. Levenson, Director of the SEC’s Boston Regional Office. “The SEC is always on the lookout for penny stock company officers and directors attempting to manipulate company stock to line their own pockets, and we will continue working closely with our law enforcement partners to detect and punish such misconduct.”

In a parallel action, the U.S. Attorney’s Office for the District of Massachusetts announced criminal charges against Withrow and Babini. Brown previously pled guilty to charges that included making false statements to the SEC during its investigation.

According to the SEC’s complaint filed in federal court in Boston:

Withrow and Babini used a Swiss trustee and foreign accounts to conceal their control over approximately 40 million shares of Endeavor Power stock, which they planned to dump into the market after hiring others to send blast e-mails touting the company.

Prior to promoting the stock, Babini and Brown engaged in manipulative trading to artificially inflate or “walk up” Endeavor Power’s share price from 7 cents to 25 cents.

Once the misleading touting campaign was underway, Babini attempted to lure additional investors by arranging to have his trades essentially reported twice in order to greatly exaggerate the demand for Endeavor Power’s stock being reported to the public.

Before most of the covertly owned shares could be sold into the market, the SEC suspended trading in Endeavor Power’s securities on March 8, 2013, due to concerns about the accuracy of assertions in the company’s public filings and press releases.

The SEC’s complaint charges Withrow, Babini, and Brown with violating the antifraud provisions of the federal securities laws and related rules. Withrow also is charged with failing to file the requisite reports with the SEC disclosing his ownership of Endeavor Power stock. The SEC seeks a final judgment ordering Withrow, Babini, and Brown to pay disgorgement of ill-gotten gains plus prejudgment interest and penalties. The SEC also is seeking permanent injunctive relief, penny stock bars against all three men, and an officer-and-director bar against Withrow.

The SEC’s investigation was conducted by Andrew J. Palid and Mark Albers of the Boston Regional Office and supervised by Michele T. Perillo. The SEC’s litigation will be led by Martin F. Healey. SEC attorney Eric A. Forni has been appointed a Special Assistant U.S. Attorney in the parallel criminal case. The SEC appreciates the assistance of the U.S. Attorney’s Office for the District of Massachusetts, Federal Bureau of Investigation, and Financial Industry Regulatory Authority.

###

http://www.sec.gov/news/pressrelease/2015-192.html

[DaReal]

PRLX now Owner of RoxSan per the last 10Q

On August 13, 2015 (the "Closing Date"), pursuant to a resolution of the board of directors, the Company entered into an Agreement to Purchase and Sell One Hundred Percent of the Issued and Outstanding Shares of RoxSan Pharmacy, Inc., a California corporation, ("RoxSan" or the "Pharmacy"), and its Assets and Inventory (the “Purchase Agreement”). Pursuant to the Purchase Agreement between the Company, RoxSan and its sole shareholder, Shahla Melamed (the “Seller”), in exchange for 100% of RoxSan's common stock, and its assets and inventory, the Company, among other things, issued the Seller a Secured Promissory Note (the "Note") dated August 13, 2015 in the amount of $20.5 million (the "Acquisition"). The Note bears interest at a rate of 6% per annum, and matures in three (3) years, or August 13, 2018 ("Maturity"). Principal and interest payments on the Note will be made to the Seller on a quarterly basis beginning with the three month period ending November 30, 2015, in an amount equal to 1) 75% during the first two (2) years; and 2) 60% during year three (3); of certain of the Pharmacy's earnings defined within the Purchase Agreement as EBITDA. All remaining principal and/or accrued interest, if any, still owing after three (3) years shall be paid in full to the Seller at Maturity.


As a result of the Acquisition, effective August 13, 2015, RoxSan became a wholly owned subsidiary of the Company. No change in control of the Company occurred as a result of the Acquisition.

[Phoenixxx]

Interesting days ahead.

[windough-shopper]

$PRLX, when the deal is done, and now, its assured teh deal will be done, the stock is .50, at least.....

[windough-shopper]

$PRLX, that they have ammended the deal for yrs and fought to get it and even sued the State when they wouldnt give em teh license

I say (IMO), its a done deal

[ufc_champ]

On July 31, 2015, the Company received notice that pharmacy and sterile compounding licenses were issued to the Company by the California State Board of Pharmacy, in connection with the Company ’ s pending acquisition of a California-based Pharmacy.


Pending an acquisition of a pharmacy is the the part you left out of your post. So it didn't sound like they are ready. Or did they already buy a pharmacy?

[windough-shopper]

$PRLX gets the license to buy pharma after so many yrs

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10844946

ITS READY!

[Phoenixxx]

Let's sniff some money soon.

[DaReal]

Lawsuits filed against the CA Board of Pharmacy


Roxsan Pharmacy, Inc. et al v. Virginia Herold et al
Defendant: California Board of Pharmacy, Does and Virginia Herold
Plaintiff: Shahla Keyvanfar Melamud and Roxsan Pharmacy, Inc.
Case Number: 2:2015cv05524
Filed: July 21, 2015
Court: California Central District Court
Referring Judge: John E. McDermott
Presiding Judge: Otis D. Wright
Nature of Suit: Civil Rights: Other


Parallax Health Sciences, Inc. v. Virginia Herold et al
Defendant: California Board of Pharmacy, Does and Virginia Herold
Plaintiff: Parallax Health Sciences, Inc.
Case Number: 2:2015cv05526
Filed: July 21, 2015
Court: California Central District Court
Presiding Judge: Christina A. Snyder
Referring Judge: Andrew J. Wistrich
Nature of Suit: Civil Rights: Other

---------

Coincidence?

[DaReal]

CC Comin, finally a Sign of Life from this Co

Parallax Health Sciences, Inc. Announces Corporate Update Conference Call

10/24/2014 SANTA MONICA, CA / ACCESSWIRE / Parallax Health Sciences, Inc. (“Parallax” or the “Company”) (OTCQB: PRLX) has scheduled a public conference call on Thursday, October 30, 2014, at 2:30pm PDT (5:30pm EDT). During the call, Edward W. Withrow III, the Company’s Chairman, and Mr. J. Michael Redmond, the Company’s President and CEO, will provide a corporate update.
------------------------------------------------------------------
|Call Length: |1 Hour |
------------------------------------------------------------------
|Conference Date: |Thursday, 10/30/2014 |
------------------------------------------------------------------
|Conference Start Time: |2:30pm PDT (5:30pm EDT) |
------------------------------------------------------------------
|Participant Dial-In Number: |1-857-232-0158 | Access Code 964308|
------------------------------------------------------------------

http://www.accesswire.com/viewarticle.aspx?id=421980

[DaReal]

Closing Date now 31st July:

Effective July 14, 2014, pursuant to an Amendment to the Agreement to Purchase and Sell One Hundred Percent of the Issued and Outstanding Shares of a California Corporation (the Pharmacy ” ) and Its Assets and Inventory (the “ Purchase Agreement ” ) between the Company and the Pharmacy and its sole shareholder (the “ Seller ” ), the Closing Date has been changed to July 31, 2014 .

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10101602

[JerseyDrew]

It hasn't done much. I figured when it came back they would do something big but nothing yet.

[Shavasana]

I am invested in a company that just got suspended by SEC. Looks like this is only ticker to come back from purgatory. Anyone care to give a history lesson?

[windough-shopper]

someone HIT my bid

PLEASE

[DaReal]

Per the given Hints in the last 8K:

About The Pharmacy
The Pharmacy, established over 60 years ago, is a compound pharmacy, headquartered in California US, specializing in infertility treatments, pain management, and individualized treatments to its clientele. The Pharmacy provides specialty compounding and full-service pharmaceutical services to healthcare professionals in 40 states in the US.

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9929099

googled: "60 y/o compound pharmacy located in CA specializing in infertility"

the only matching Hit for a Parmacy with a 60yr history that matches all criterias was a Company named Rox San
https://www.roxsan.com/



Congrats to all players, if true and with the given Float of just 4.2M shares this thing could start to take-off upon confirmation imo.

[Cobra Kai]

very interesting find Penny Buster

[Pennybuster]

:)

[windough-shopper]

waiting for the deal to be DONE

I will buy more

[Druides]

Yes I think this has 400% return all over it from these levels.imo Not many caught on to 8K. Got my shares. Just got to wait now.

[TEFFY]

sounds good

[windough-shopper]

PRLX.....look at AGOE, they did a similiar deal, though NOT as big, the stock went from 20 to 70.......(and will go farther)(granted, AGOE has less shares)

When PRLX has teh deal DONE

PRLX is 50, if not 70

[Druides]

ic thanks. Yes a no brainer here. Looks really good.

[windough-shopper]

PRLX....cause

1-No one knows

2-No PR

Wait till the deal is DONE

.50-.75, easy!